Tomivosertib (eFT-508)
Phase 1/2Terminated 1 views this week 0 watching💤 Quiet
Interest: 14/100
14
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma
Conditions
Lymphoma
Trial Timeline
Feb 8, 2017 → Apr 4, 2019
NCT ID
NCT02937675About Tomivosertib (eFT-508)
Tomivosertib (eFT-508) is a phase 1/2 stage product being developed by eFFECTOR Therapeutics for Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02937675. Target conditions include Lymphoma.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma were approved
Approved (18) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
9
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03616834 | Phase 2 | Completed |
| NCT02937675 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Lymphoma